← Eichor
Study identifier: NCT06208735 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

Condition: B-Cell Leukemia · Non-Hodgkin's Lymphoma · B-cell Acute Lymphoblastic Leukemia  ·  Sponsor: British Columbia Cancer Agency

PhasePhase 1
Planned participants24
Who can joinAll sexes, 1 Year to no upper limit
Healthy volunteersNo

About this study

This is a phase I dose-finding trial of an autologous CD22 targeting chimeric antigen receptor (CAR)-T cell product, called CLIC-2201, for participants with relapsed/refractory B cell malignancies. In the proposed trial, eligible enrolled participants will undergo leukapheresis for autologous T cell collection to enable CLIC-2201 manufacturing, followed by lymphodepletion with cyclophosphamide and fludarabine, then intravenous infusion of the autologous CLIC-2201 product. The trial will use the 3+3 design to escalate or de-escalate the dose level of CLIC-2201 administered. Participants will be monitored for safety and tolerability up to day 365 following CLIC-2201 infusion. The primary objective is to evaluate the safety and tolerability of CLIC-2201 and estimate the maximum tolerated dose (MTD) of CLIC-2201 in B-cell malignancies. The secondary objectives are to evaluate the (i) feasibility; (ii) anti-tumour activity of CLIC-2201; (iii) and characterize the pharmacokinetic (PK) profile of CLIC-2201. Exploratory objectives will include: i) characterizing the cellular and humoral immune responses against CLIC-2201 up to 1 year following infusion of CLIC-2201; (ii) characterizing the phenotype and gene expression profile of CLIC-2201 cells; (iii) evaluating immune and tumour cells at baseline and relapse for biomarkers of response or toxicity; (iv) evaluating serum cytokines, circulating tumour DNA (ctDNA) and B cell aplasia as biomarkers of clinical outcomes; and (v) assess…

This description comes directly from the study's public registry record.

Talk to the study team

Kevin Hay, MD  ·  (403) 210-6191  ·  kevin.hay@bccancer.bc.ca

Narsis Afghari, MSc  ·  (604) 675-4100  ·  narsis.afghari@bccancer.bc.ca

Always discuss trial participation with your own doctor first.

Locations (7)

Arthur J.E. Child Comprehensive Cancer CentreCalgary, Alberta, CanadaRecruiting
Alberta Children's HospitalCalgary, Alberta, CanadaRecruiting
Vancouver General HospitalVancouver, British Columbia, CanadaRecruiting
BC Children's HospitalVancouver, British Columbia, CanadaRecruiting
The Ottawa Hospital - General CampusOttawa, Ontario, CanadaRecruiting
Princess Margaret Cancer CentreToronto, Ontario, CanadaRecruiting
The Hospital for Sick ChildrenToronto, Ontario, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06208735